Skip to main content

Table 1 Available medical records of the CLL patients analyzed

From: Evaluation of Caspase-9b and PP2Acα2 as potential biomarkers for chronic lymphocytic leukemia

Patient Age at diagnosis Previous treatments White blood cells Hemoglobin Platelets Matutes score Binet score Caspase-9b PP2Acα2
CLL15 71 NO 100000 10.2 86 4 C 0.05 11.93
CLL13 56 NO 97000 11.7 230 5 B 0.05 5.73
CLL12 63 NO 85000 12.7 116 5 B 0.10 3.96
CLL21 64 NO 110000 9.8 95 5 B 0.13 3.80
CLL6 82 NO 28000 10.6 206 5 B 0.57 3.74
CLL19 60 YES 230000 12.5 90 5 B 0.09 2.26
CLL5 72 NO 200000 12.9 92 5 A 1.90 3.68
CLL2 78 NO 100000 12.3 223 4 A 0.55 2.19
CLL1 50 NO 130000 10.9 189 5 A 1.34 1.89
CLL20 68 NO 87000 10.6 120 5 A 0.12 1.87
CLL16 43 NO 44000 15.0 210 5 A 0.06 1.38
CLL11 75 NO 25000 14.2 186 4 A 0.14 1.24
CLL4 72 NO 27000 14.6 250 5 A 1.30 1.02
CLL3 68 NO 80000 13.1 188 5 A 0.83 0.82
CLL17 87 NO 140000 10.1 66 5 A 0.11 0.38
  1. Age, treatment with fludarabin (in the case of CLL19), hematological parameters and Matutes score (that confirms these patients as CLL) registered in medical records for some of the patients analyzed are compiled in this table. Binet score B and C, indicating advanced stages of the disease, are highlighted in bold. Normalized values of relative abundance of Caspase-9b and PP2Acα2 have been added to the table